Mode
Text Size
Log in / Sign up
N/A N=50 Randomized Treatment

SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue

Sarcoidosis · Fatigue

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcome: Primary: Proportion of Participants Recruited — 25; 25 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Sarcoidosis Patient Assessment and Resource Companion App (Behavioral); Enhanced Standard Care (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medical University of South Carolina
Primary completion
Dec 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Proportion of Participants Recruited
25; 25
PRIMARY
Number of Participants Who Complete the Study
25; 24
PRIMARY
Number of Participants Who Maintain Adherence to at Least Daily Daily Breathing Awareness Meditation Sessions
10; 15
PRIMARY
Treatment Satisfaction
60.4; 49.1
SECONDARY
Change in Sarcoidosis Associated Fatigue From Baseline to Month 6
-7.1; 0.4
SECONDARY
Changes in Self-Efficacy From Baseline to Month 3
10.6; 0.6
SECONDARY
Changes in Stress From Baseline to Month 6
-5.0; -1.2
SECONDARY
Changes in Autonomous Motivation
SECONDARY
Changes in Quality of Life
11.7; 1.3

Summary

Fatigue is a pervasive and disabling symptom in sarcoidosis with limited treatment options. There is a significant association between heightened stress and sarcoidosis-associated fatigue. The proposed project will evaluate the usability/feasibility of a smartphone-based stress management application for the self-management of sarcoidosis-associated stress and fatigue.

Eligibility Criteria

Inclusion Criteria

  • Sarcoidosis diagnosis based on established criteria
  • ≥18 years old
  • able to speak, hear, and understand English
  • elevated SAF (FAS score ≥22)
  • owns smartphone with current data plan
  • willingness and ability to use app to engage in Breathing Awareness Meditation (BAM)

Exclusion Criteria

  • history of psychotic disorder, bipolar disorder, eating disorder, narcolepsy, cancer diagnosis or treatment in past 12 months
  • positive screening for potential major depression (Patient Health Questionnaire depression scale [PHQ-8; α = .86] score ≥10)
  • untreated sleep apnea (based on home sleep study testing)
  • sarcoidosis exacerbation in past 3 months requiring increase in sarcoidosis medications
  • >2 hr travel distance to medical center (to reduce likelihood of no-show for focus groups)
  • active substance abuse or binge drinking (>21 drinks/week )
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05230693). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search